3Zioncheck TF, Powell I.M, Rice GC, et al. Interaction of recom branat Apo(a) and Lp(a) with amcrophages[J]. Jclin Invest,1991,87(3) : 767-771.
4Torzewski J, Torzewski M, Bowyer DE, et al. C - reactive protein fre - quentlycolocalizes wieth the terminal complment complex in the intima of early atherosclerotic lesions of human coronary arteries[ J ]. Arterioscler Thromb Vasc boil, 1998, 18 ( 9 ) :1386-1392.
5Anderson JL, Carlquist JF, Muhlestein JB, et al. Eviluation of C- reactiveprotein, an inflammatory maker infectious serology asrisk factors for coronary artery disease and myocardial infarction[J ]. J Am Coil Cardiol, 1998, 32( 1 ) :35-41.
4Third report of the National Cholesterol Education Program (NCEP).Expert panel on detection,evaluation and treatment of high blood cholesterol in adult(Adult treatment panol Ⅲ),Final Report,2002(106).
5李健斋.老年人血脂异常与冠心病及其防治问题,2003(01).
6Japanese Association of Arteriosclerosis.Guideline for diagnose and treatment hyperlipidemia in adult,1997.
7Report of a WHO consultation:Definition,diagnosis and classification of Diabetes Mellitus and its complication,1999.
8Sacks DB;Bruns DE;Goldstein DE.Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J],2002.
9Park YW;Zhu S;Palaniappan L H.The metabolic syndrome:prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Survey,1988-1994[J],2003.
2Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening[J]. Clin Chem, 2001, 47(1): 28-30.
3Eren E, Yilmaz N, Aydin O. High density lipoprotein and it's dysfunction[J].Open Biochem J, 2012, 6: 78-93.
4Saito M, Ishimitsu T, Minami J, et al. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors[J]. Atherosclerosis, 2003, 167(1): 73-79.
5Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries[J]. Arterioscler Thromb Vasc Biol, 1998, 18(9): 1386-1392.
6Pedersen TR, Cater NB, Faergeman O, et al. Comparison of atorvastatin 80mg/day versus simvastatin 20 to 40mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)[J]. Am J Cardiol, 2010, 106(3): 354-359.
7Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease[J]. J Am Osteopath Assoc, 2005, 105(9): 409-416.
